http://repository.usmf.md:80/xmlui/handle/20.500.12710/651 2026-04-20T15:26:36Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/31239 Frailty syndrome in heart failure: from definition to biomarkers Ivanes, Anastasia A.; Vetrilă Snejana, Boris; Grib, Livi T. Background. In an aging society, ensuring quality of life has become a major public health priority. Rising life expectancy and the high prevalence of cardiovascular risk factors have contributed to a global increase in heart failure (HF), currently affecting over 64 million people. At the same time, frailty syndrome (FS) – once considered a condition of the elderly – is now recognized in younger adults as well, categorized as early frailty (<65 years) and late frailty (≥65 years). FS is a multidimensional condition characterized by diminished physiological reserves and increased vulnerability to stressors, which significantly contributes to disability, hospitalizations, and mortality among patients with HF. This review aims to synthesize recent evidence on the definition, assessment, and prognostic value of biomarkers related to FS in individuals with HF. Materials and methods. This review analyzes 10 peer-reviewed studies published between 2022 and 2025, selected from PubMed, NCBI, and Google Scholar. The selected articles focused on frailty in the context of HF, including clinical definitions, diagnostic tools, and relevant biomarker profiles. Results. The concept of frailty has evolved from the Fried physical phenotype model to broader frameworks encompassing physical, psychosocial, and cognitive domains. Biomarkers with diagnostic and prognostic relevance in FS include inflammatory markers (IL-6, TNF-α, CRP), oxidative stress indicators, hormonal decline markers (testosterone, DHEA-S), and sarcopenia-related markers (myostatin, serum creatinine). Moreover, emerging research areas – such as adiponectin levels, epigenetic regulation, and gut microbiota composition – have been implicated in the pathophysiology of frailty in HF. Conclusions. Frailty syndrome is a major determinant of adverse outcomes in patients with HF, regardless of age. The identification of specific biomarkers offers promising avenues for early diagnosis, individualized risk stratification, and targeted interventions. Integrating biomarker-based assessments into routine clinical practice could enhance prognostic precision and alleviate the healthcare burden associated with HF and frailty. 2025-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/30035 Oxidative stress in patients with community-acquired pneumonia and pre-existing heart failure Grib, Livi; Fetco-Mereuță, Diana; Caproș, Natalia; Dumitraș, Tatiana; Cașcaval, Virginia; Matcovschi, Sergiu 2024-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/29935 Determinants of patient readmissions in the first two years after coronary revascularization therapy Bursacovschi, Daniela; Cazacu, Jana; Lîsîi, Dorin; Vataman, Eleonora 2021-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/29934 Evaluation of left ventricular function in patients with Non-Hodgkin’s lymphoma undergoing chemotherapy Bursacovschi, Daniela; Revenco, Valeriu; Robu, Maria Introduction. Non-Hodgkin's lymphoma is the most common hematologic malignancy with an increased risk for cardiovascular complications due to the applied treatment. Echocardiographic evaluation could lead to early detection of cardiotoxicity. Materials and methods. A sample of 83 consecutive patients who underwent chemotherapy (CTx), excluding those who received chemo- or radiotherapeutic treatment, with known coronary/myocardial diseases, moderate or severe valvulopathies. Echocardiography was performed at baseline, and at 6-month follow-up. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as new left ventricular ejection fraction (LVEF) reduction by ≥10 percentage points to an LVEF of 40–49%. Results. LVEF decreased from 63.2 ± 4.5 % to 57.5 ± 4.7 % during follow up (p <0.001), also significantly increased the left ventricular end-diastolic diameter from 47.2 ± 5.2 mm to 54.3 ± 5.3 mm (p <0.001), other parameters as the left-ventricular myocardial performance index and systolic velocity of mitral septal annulus did not achieve statistically significant differences (p = 0.560 and p = 0.430 respectively). E/e’ was 10.3 ± 4.3 increased to 11.4 ± 5.6 (p=0.233), left atrial volume index increased from 29.4 ± 5.6 ml/m2 to 36.2 ± 4.3 ml/m2 (p < 0.001), the ratio of color M-mode flow propagation velocity to early diastolic trans – mitral flow velocity (E/ Vp) increased at 6-month follow-up compared with baseline (1.6 ± 0.3 and 1.3 ± 0.4, p < 0.001, respectively). CTRCD was assessed in 9 patients (9.63%). Conclusion. CTx has an impact on left ventricular function and the parameters above could be used for predicting CTRCD. 2023-01-01T00:00:00Z